HBM HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.38 HKD | -1.43% |
|
-6.12% | -28.87% |
| Apr. 02 | HBM Holdings Returns to Profitability in 2023 | MT |
| Mar. 28 | HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 40.66M 317M | Sales 2023 | 89.5M 698M | Capitalization | 182M 1.42B |
|---|---|---|---|---|---|
| Net income 2022 | -137M -1.07B | Net income 2023 | 22M 172M | EV / Sales 2022 | 4.58 x |
| Net cash position 2022 | 81.58M 636M | Net cash position 2023 | 74.71M 583M | EV / Sales 2023 | 1.19 x |
| P/E ratio 2022 |
-1.91
x | P/E ratio 2023 |
8.28
x | Employees | 177 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 79.42% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.43% | ||
| 1 week | -6.12% | ||
| Current month | +16.95% | ||
| 1 month | +26.61% | ||
| 3 months | -16.36% | ||
| 6 months | -13.75% | ||
| Current year | -28.87% |
1 week
1.38
1.50
1 month
1.011.60
Current year
1.011.95
1 year
1.012.03
3 years
0.8712.40
5 years
0.8712.40
10 years
0.8712.40
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Song Wang
CEO | Chief Executive Officer | 60 | 16-07-19 |
Weihao Xu
DFI | Director of Finance/CFO | 42 | 21-11-30 |
Hong Amy Que
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Albert Collinson
BRD | Director/Board Member | 66 | 23-07-12 |
Robert Kamen
BRD | Director/Board Member | 79 | 16-11-30 |
Wei Wei Chen
BRD | Director/Board Member | 58 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.78% | 4 M€ | -27.92% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 1.38 | -1.43% | 2 068 000 |
| 24-05-16 | 1.4 | -2.78% | 1,904,000 |
| 24-05-14 | 1.44 | +1.41% | 782,000 |
| 24-05-13 | 1.42 | -3.40% | 3,076,000 |
| 24-05-10 | 1.47 | -4.55% | 2,693,000 |
Delayed Quote Hong Kong S.E., May 17, 2024 at 04:08 am EDT
More quotes
HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Companyâs products include batoclimab, mainly used for immune thrombocytopenia (ITP), gravesâ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.87% | 131M | |
| -2.32% | 92.59B | |
| +3.16% | 41.43B | |
| -11.10% | 33.49B | |
| +53.49% | 25.06B | |
| -9.41% | 12.77B | |
| -12.25% | 11.58B | |
| -44.00% | 11.35B | |
| +6.07% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- 2142 Stock
